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ABSTRACT:Chronic obstructivepulmonarydisease (COPD) is agrowingcauseofmorbidity andmortalityworldwide.
Cigarette smoke (CS) exposure, amajor cause of COPD, dysregulates airway epithelial ion transport and diminishes
airway surface liquid (ASL) volume. Short palate lung and nasal epithelial clone 1 (SPLUNC1) is secreted into the
airway lumen where it maintains airway hydration via interactions with the epithelial Na1 channel (ENaC). Al-
though ASL hydration is dysregulated in CS-exposed/COPD airways, effects of CS on SPLUNC1 have not been
elucidated. We hypothesized that CS alters SPLUNC1 activity, therefore contributing to ASL dehydration. CS ex-
posure caused irreversible SPLUNC1 aggregation and prevented SPLUNC1 from internalizing ENaC and main-
tainingASL hydration. Proteomic analysis revealedab-unsaturated aldehydemodifications to SPLUNC1’s cysteine
residues.Removalof thesecysteinespreventedSPLUNC1fromregulatingENaC/ASLvolume. In contrast, SPX-101, a
peptidemimetic of natural SPLUNC1, that internalizes ENaC, but does not contain cysteines was unaffected by CS.
SPX-101 increasedASL hydration and attenuated ENaC activity in airway cultures after CS exposure and prolonged
survival in a chronic airway disease model. These findings suggest that the CS-induced defects in SPLUNC1 can be
circumvented, thusmakingSPX-101 anovel candidate for the treatment ofmucusdehydration inCOPD.—Moore, P.
J., Reidel, B., Ghosh, A., Sesma, J., Kesimer, M., Tarran, R. Cigarette smoke modifies and inactivates SPLUNC1,
leading to airway dehydration. FASEB J. 32, 6559–6574 (2018). www.fasebj.org
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Cigarette smoke (CS) contains a complex mixture of more
than 5000 chemicals that can interactwith airway epithelia
(1). Harmful, volatile constituents of tobacco smoke in-
clude acetaldehyde, acrolein, and crotonaldehyde (2). Of
note, crotonaldehyde and acrolein are 2 of the strongest
electrophiles among ab-unsaturated aldehydes that are
present in CS and CS extract and can cause DNA and
protein adduct formation (3, 4). Indeed, inhalation of CS
introduces exogenous reactive oxidants into the airways
and causes the generation of endogenous oxidants that are
released by the lung (5). For example, acrolein fromCS can
induce adduct formation on surfactant protein A, which
results in a loss of function and decreased levels of sur-
factant protein A in patients with chronic obstructive
pulmonary disease (COPD) compared with healthy indi-
viduals (6, 7). Furthermore, acroleinmodifies extracellular
matrix proteins and reduces their ability to interact with
macrophages, which results in decreased phagocytosis of
apoptotic neutrophils (8). Acrolein also forms adducts
with apolipoprotein E, which results in changes in protein
folding and a loss of function (9).
COPD is the fourth leading cause of death worldwide
and is most often caused by chronic CS exposure (10).
COPDmanifests as 2 major phenotypes, emphysema and
chronic bronchitis (CB). The CB form of COPD is charac-
terized by chronic airway inflammation and an increase in
mucus production that results in irreversible airflow ob-
structionanda subsequentdecline in lung function (11, 12).
Althoughcurrent therapies, suchas anti-inflammatoryand
bronchodilator therapies, are available, they fail to stop
disease progression, and, at present, there is no cure for
CB/COPD. Located at the interface between the host and
the environment, the airway surface liquid (ASL) repre-
sents the first line of defense against inhaled CS toxicants.
ASL volume homeostasis is controlled by cystic fibrosis
transmembrane conductance regulator (CFTR) –mediated
anion secretion and epithelial Na+ channel (ENaC)
–mediated Na+ absorption (13). CS exposure has been
shown to inhibit CFTR without inhibiting ENaC, which
leads to ASL dehydration (14–17). ASL/mucus de-
hydration leads to a failure to clear mucus from the lung
and an increase in mucus plugging. Indeed, ASL
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dehydration closely correlateswith thedecline in FEV1 in
patients with COPD, which suggests that restoring ASL
hydration may be beneficial for these patients (18).
The short palate, lung, and nasal epithelial clone 1
(SPLUNC1), also known as bactericidal/permeability in-
creasing family member A1 (BPIFA1), is a 256-aa protein
secreted into the airway lumen (19). SPLUNC1 negatively
regulates ENaC to limit ASL absorption (20). This in-
teractionoccursvia theN-terminalS18regionofSPLUNC1
and the b-subunit of ENaC (21); however, additional do-
mains on the main body of SPLUNC1 can also influence
this interaction. For example, we have previously dem-
onstrated that pH-sensitive salt bridges on SPLUNC1
modulate the ability of theS18 region tobind toENaC (22).
SPLUNC1 also contains 2 cysteine residues at positions
180 and 224 thatmay form intermolecular disulfide bonds
(21). Although salt bridges play a critical role in ENaC
regulation, the role of disulfide bonds in the ability of
SPLUNC1 to modulate ENaC and ASL volume is less
clear.
SPX-101 is a novel peptidemimetic of natural SPLUNC1
that induces ENaC internalization to attenuate trans-
epithelialNa+absorption, thereby increasingASLhydration
(23). SPX-101 increased survival rates in b-ENaC–
overexpressing transgenic mice that spontaneously de-
veloped lung disease (23, 24) and restoredmucus transport
in an ovine model in which CFTR was pharmacologically
inhibited (23). As patients with COPD suffer from mucus
dehydration as a result of mucus hypersecretion and re-
duced levels ofCFTR,SPX-101mayserveasanovel therapy
with which to treat individuals with CB/COPD. Although
the biologic effects of CS are diverse, few studies have ex-
amined the effects of CS on secreted airway proteins. Here,
we tested the hypothesis that CS exposure adversely affects
the structure/function of SPLUNC1, which contributes to
CS-induced ASL dehydration, and that this dysregulation
can be restored with the addition of SPX-101.
MATERIALS AND METHODS
SPLUNC1 purification
Aplasmid that contained SPLUNC1 cDNAwas transformed into
BL21-CodonPlus competent cells (Agilent Technologies, Santa
Clara, CA, USA) and purified as previously described (21). After
purification, all recombinant SPLUNC1 proteins were produced
as described previously and stored at 280°C until required
(21). Recombinant SPLUNC1 proteins tested here included
SPLUNC1D19, which lacks the cleavable N-terminal signal se-
quence (residues M1–M19) but is otherwise full length (re-
ferred to as rSPLUNC1). rSPLUNC1C180A, rSPLUNC1C224A, and
rSPLUNC1C180A/C224A were generated using rSPLUNC1D19 by
site-derived mutagenesis and where noted were labeled with the
DylightNHSEsterDyes (ThermoFisher Scientific,Waltham,MA,
USA) according to the manufacturer’s protocol.
CS exposure
Human bronchial epithelial cultures (HBECs) were placed in a
chamber that exposed apical surfaces, but not basolateral sur-
faces, to CS (25). CSwas then generated fromKentuckyResearch
cigarette (3R4F) by generating a 35-ml draw over 2 s using a
smoke engine (Borgwaldt, Richmond, VA, USA) applied to cul-
tures at a rateof 1puff every30 suntil the cigarettewas exhausted
(;13 puffs over ;5 min). This protocol has previously been
shown to internalize CFTR from the plasma membrane without
inducing cellular toxicity (16). To investigate the effect of
rSPLUNC1 under cell-free conditions, protein was dissolved in
Ringer’s solution and 100ml of this solutionwas placed in a petri
dish and exposed to 13 puffs over 5 min. To determine whether
the effects of CS were reversible, Ringer’s solution, CS Ringer’s
solution, rSPLUNC1 (40 mM), and CS rSPLUNC1 (40 mM) were
dialyzed overnight in 10-kDa dialysis cassette (Thermo Fisher
Scientific) in buffer (11.57 mM Na2HPO40.7H2O, 79 mM
NaH2PO4, 150 mM NaCl). For SPX-101 ASL experiments, SPX-
101 (10 mM) was exposed to CS under cell-free conditions in the
smoke chamber and subsequently added apically to HBECs. To
examine the prophylactic effects of SPX-101 on CS, exposed
HBECs were pretreated with SPX-101 for 30 min and HBECs
were exposed to CS (17). For ASL height recovery studies, cells
were treated with CS for;5 min and placed in an incubator for
30 min before addition of SPX-101 as a suspension in per-
fluorocarbon (MilliporeSigma, Burlington, MA, USA) as pre-
viously described (26).
HBEC mucosal binding assay
For the HBEC mucosal binding assay, rSPLUNC1 protein was
labeled with amine-reactive Dylight 633 (Thermo Fisher Sci-
entific) per the manufacturer’s instructions. Dexamethasone
(100nM;MilliporeSigma)wasaddedbasolaterally toHBECs24h
before the experiment. On the day of the experiment, HBECs
werewashedmucosally with PBS and freshmediumwas added
serosally. Cells were loaded with calcein-AM (Thermo Fisher
Scientific) for 30 min before apical addition of fluorescently la-
beled SPLUNC1. Fluorescent SPLUNC1 and CS SPLUNC1
(40 mM) was added apically in 20 ml modified Ringer’s solution
and incubated for 6 h at 37°C. Cultures were then washed
mucosally 3 times with 500 ml of 4°C PBS to remove unbound
rSPLUNC1, and serosalmediumwas replacedwith 4°Cmedium.
Cultureswere then imagedusingaLeicaSP8 confocalmicroscope
Leica Microsystems, Wetzlar, Germany) with a363 glycerol im-
mersion objective. Dylight 633 fluorescence was acquired using a
He-Ne 633 nm laser, with emission collected from 640–680 nm.
ASL height measurements
ASLheightwasmeasuredonHBECs that hadbeengrownunder
air-liquid interface conditions for 3–4 wk and subsequently
washed twice with 500 ml of PBS for 30 mins to remove endog-
enous ASL as described (27). HBECs were incubated with 20 ml
Ringer’s solution that contained 40 mM rSPLUNC1 or Ringer’s
solution (control) as indicated. In all cases, 10 kDa tetrame-
thylrhodamine dextran (Thermo Fisher Scientific) at 1 mg/ml
was added to label the ASL. After 6 h at 37°C, ASL height was
measured using 10 predeterminedpoints on a Leica SP5 confocal
microscope with a 363 glycerol immersion objective as pre-
viously described (21). Perfluorocarbon was added apically be-
fore imaging to prevent ASL evaporation (13).
Western blot assays
Purified rSPLUNC1 was exposed to air or CS and denatured
using 2-ME (MilliporeSigma). Samples were separated by SDS-
PAGE and transferred to PVDF membranes. Membranes were
blocked with 5% skimmed milk in Tris-buffered saline with
Tween 20 for 1 h at room temperature and were then incubated
with a SPLUNC1 Ab (R&D Systems, Minneapolis, MN, USA)
diluted 1:5000 with 5% milk at 4°C overnight. Horseradish
Microelectrode studies
Asingle-barreled transepithelial potential difference (Vt) –sensing
microelectrode was positioned in the ASL by micromanipulator
and used in conjunction with a macroelectrode in the serosal
solution to measure Vt with a voltmeter (World Precision
Instruments, Sarasota, FL, USA) as previously described (26).
All experiments were performed with 10 mM bumetanide
(MilliporeSigma) added serosally to inhibit chloride secretion.
Perfluorocarbonwas added to themucosal surface during the
period of recording to avoid ASL evaporation.
Internalization assay
HEK293T cells were cultured in 10-cm dishes and subsequently
transfected overnight with aENaC-GFP, b-, and g-ENaC, and
CFTR-GFP. Cells were trypsinized and seeded in a 96-well plate
at a density of 60,000 cells/well and incubated for 8 h at 37°C and
5% CO2 to allow cells to recuperate. On the same day, cells were
incubated with Ringer’s solution, CS Ringer’s solution, 40 mM
rSPLUNC1, and CS rSPLUNC1 for 1 h at 37°C/5%CO2. Ten
micromolar SPX-101 andCS-SPX-101, and1mMcrotonaldehyde
(MilliporeSigma) was also added for 1 h at 37°C/5% CO2.
Fluorescence was read using a Tecan Infinite M1000 Multiplate
Reader (Tecan Group, Männedorf, Switzerland) at 37°C.
Mass spectrometry analysis
CS- and air control–exposed rSPLUNC1 (40 mM) and SPX-101
(10 mM) were immediately prepared for mass spectrometry anal-
ysis by filter-aided sample preparation (33). First, each samplewas
spin filtered at 14,000 g via Amicon Ultra 4 10-kDa spin filters
(EMD Millipore, Billerica, MA, USA) and washed 2 times with
50 mM ammonium bicarbonate to remove soluble components
after CS exposure. The remaining material in the filter that
was.10 kDaMWwasdigested overnightwith trypsin (20 ng/ml)
in 50mMammoniumbicarbonate at 37°Cor chymotrypsin (25ng/
ml) in 100 mM Tris HCl that contained 10 mM CaCl2 at room
temperature. The resulting peptide digests were eluted using
AmiconUltra 4 10-kDa spin filters. Peptidemixeswere vacuum
freeze dried and dissolved in 25 ml of 2% acetonitrile and 0.1%
trifluoroacetic acid. Five microliters of solubilized peptide
material were injected for proteomic analysis using a Q Ex-
active (Thermo Fisher Scientific) mass spectrometer coupled to
anUltiMate 3000 (Thermo Fisher Scientific) nano-HPLC system.
Data acquisition was performed as previously described (34).
Proteomic data analysis
Acquired raw data were processed using Proteome Discoverer
1.4 software (Thermo Fisher Scientific) and searched against the
SwissProt protein database (Homo sapiens, November 2016),
and the custom sequence of the SPX-101 peptide was searched
using the Mascot (Matrix Science, Boston, MA, USA) search en-
gine with parameters set as follows: 5-ppm mass accuracy for
parent ions and 0.02-Da accuracy for fragment ions, with 2
missed cleavages allowed. To identify modified peptides of
smoke-exposed rSPLUNC1, the Mascpt search algorithm was
first set to error-tolerant mode, followed by trypsin- and
chymotrypsin-specific searches with variable methionine oxida-
tion, as well as crotonaldehyde and acrolein modification of cys-
teines. Scaffold 4.7.5 (Proteome Software, Portland,OR,USA)was
used to validate tandem mass spectrometry–based peptide and
protein identifications. Peptide identifications were accepted if
they could be established at.95.0%probability using the Scaffold
Local false-discovery rate algorithm. Protein identifications were
peroxidase–conjugated anti-goat Ab was used as secondary Ab 
to detect rSPLUNC1 by ECL (Thermo Fisher Scientific). Where 
indicated, samples were loaded onto nonreducing PAGE gels 
according to the manufacturer’s instructions (Thermo Fisher 
Scientific).
Cell culture and transfection
Normal human or COPD donor lungs and excised recipient lungs 
of normal patients were obtained at the time of lung transplantation 
from main stem/lobar bronchi by enzymatic digestions using 
protocols approved by the University of North Carolina Commit-
tee on the Protection of the Rights of Human Subjects. HBECs were 
grown from cells that were harvested by enzymatic digestion of 
human bronchial tissue and cultured on 12-mm Transwell per-
meable supports (Corning, New York, NY, USA) and maintained 
at an air-liquid interface for ;4 wk in UNC air-liquid interface 
medium at 37°C/5% CO2 as described in Randell et al. (28). All  
experiments were performed within 4 wk after seeding.
HEK293T cells were cultured in DMEM medium with 10%
fetal bovine serum (FBS), 13 penicillin/streptomycin at 37° with 
5% CO2. For surface biotinylation experiments, HEK293T cells 
were seeded on Corning tissue culture–treated 60 3 15 mm-
dishes. HEK293T cells were transfected using Lipofectamine 
2000 (Thermo Fisher Scientific) according to the manufacturer’s 
instructions when cells were 70% confluent 12 h before the ex-
periment. For each construct, 1 mg/DNA was used to transfect 
60 3 15 mm dishes, and 3 mg/DNA were used to transfect 10-cm 
plates. Human wild-type a-, b-, and g-ENaC constructs were 
used in combinations of tagged and untagged subunits. For 
double-tagged subunits, human a-, b-, and g-ENaC were each 
tagged with hemagglutinin (HA) on the N terminus and with V5 
on the C terminus as previously described (29, 30). For fluores-
cent reading, a-ENaC and CFTR were tagged with green fluo-
rescent protein (GFP) on their C termini, which were gifts from 
Dr. Deborah Baines (St. George’s University, London, United 
Kingdom) (31). The GFP-CFTR construct was donated by Dr. 
Bruce Stanton (Dartmouth College, Hanover, NH, USA) (31).
Surface biotinylation
HEK293T cells were transfected with: 1) human HA-aENaC-V5, 
b-, and g-ENaC; 2) human  aENaC, HA-bENaC-V5, and gENaC; 
and 3) human  a-, b-ENaC, and HA-gENaC-V5 (4). Cells were 
treated with 40 mM SPLUNC1 in DMEM with 10% FBS at 37°C/ 
5% CO2 for 1 h. Cells were washed with ice-cold PBS with 1 mM 
MgCl2 and 1 mM CaCl (PBS2+). Cells were incubated with 
0.5 mg/ml NHS-Biotin (Thermo Fisher Scientific) in borate buffer 
for 20 min under gentle agitation on ice. Biotinylation was 
quenched with 10% FBS in PBS2+ for 20 min on ice under gentle 
agitation. Cells were lysed with 100–200 ml biotinylation lysis 
buffer [10 mM TRIS-HCl (pH 7.4), 0.4% sodium deoychorate, 1%
NP-40, and 50 mMEGTAwith protease inhibitor cocktail; Roche, 
Basel, Switzerland]. Lysed cells were incubated on ice for 30 min 
and centrifuged for 10 min at 5000 g. Supernatantsweresubjected  
to bicinchoninic acid protein assay (Thermo Fisher Scientific), 
and an equal amount of protein was incubated with 125 ml of  
Neutravidin agarose (Thermo Fisher Scientific) under invert ro-
tation. Neutravidin beads were washed 3 times with PBS2+, and  
proteins were eluted using 23 Laemmli sample buffer (Bio-Rad, 
Hercules, CA, USA) by boiling at 95°C for 10 min. After cooling 
down, Neutravidin beads were separated from eluted proteins 
by centrifugation at 14,000 g for 3 min at room temperature. 
Supernatants were subjected to SDS-PAGE. Anti-V5 (Thermo 
Fisher Scientific) and anti–glyceraldehyde 3-phosphate de-
hydrogenase (Santa Cruz Biotechnology, Dallas, TX, USA) Abs 
were used for immunoblotting.
accepted if they could be established at .95.0% probability and
contained at least two identified peptides. Protein probabilities
were assigned using the Protein Prophet algorithm (35).
Circular dichroism
rSPLUNC1 was diluted to 10 mM in PBS buffer loaded into 1-mm
cuvettes. Using a Chirascan-Plus instrument (Applied Photo-
physics, London, United Kingdom), spectra were recorded from
200 to 260 nm at 206 1.0°C as described in Hobbs et al. (22). Mea-
surements were corrected for background signal using PBS buffer.
Dynamic light scattering
Dynamic light scattering was used to determine the size of
rSPLUNC1 after CS exposure, as previously described (21). Size
and z potential measurements were conducted using a Zetasizer
Nano ZS System (Malvern Instruments, Malvern, United
Kingdom). Ten micromolar rSPLUNC1, CS rSPLUNC1,
rSPLUNC1C180A, rSPLUNC1C224A, and rSPLUNC1C180/224A
were used for size measurements.
b-ENaC mouse studies
All mice used in these studies were on a mixed C57BL/6:C3H
background. Airway-specific b-ENaC transgenic (b-ENaC–Tg)
mice thatoverexpressed theScnn1bgene (24)wereobtained from
the University of North Carolina Marsico Lung Institute Mouse
Model Core. Mice were housed in individually ventilated MV2
Innovive cages in a specific pathogen–free facility maintained at
Spyryx Biosciences on a 12-h day/night cycle. Mice were fed a
regular chow diet and given water ad libitum. Animal E6 proto-
cols were reviewed and approved by the Institutional Animal
Care and Use Committee of Spyryx Biosciences.
Data and statistical analysis
Thenumberof replicatesperformedperexperiment isnoted in the
respective figure legends. All experiments were repeated on $3
separate occasions. All experiments conducted using HBECs
were repeated using 3–4 different donors on separate occasions
with triplicates per donor unless otherwise indicated. In-
ternalizationexperimentsusingHEK293Tcellswereconducted in
a multiwell plate on 4 separate occasions with 8 technical repli-
cates per plate. AllHBECmucosal binding andASLheight image
analyses were performed using ImageJ software (National Insti-
tutes ofHealth, Bethesda,MD,USA). ForHBECmucosal binding,
ahistogramplotwasgenerated in ImageJ anddatawere exported
to Prism 7.0 (GraphPad Software, La Jolla, CA, USA). Values that
were less than the 25% quartile range were deemed nonspecific
binding and thus excluded. Data are shown as means 6 SE. Dif-
ferences between means were tested for statistical significance
using Mann-Whitney U test, Kruskal-Wallis test with Dunn’s
multiple comparison test, 2-way ANOVA test with Tukey’s
multiple comparisons test, andKaplan-Meier log rankanalysis.
Statistical analysis was performed using GraphPad Prism 7.0,
with values of P , 0.05 considered statistically significant.
RESULTS
SPLUNC1 fails to bind to HBEC mucosal
surfaces after CS exposure
We have previously demonstrated that rSPLUNC1 binds
toHBECmucosal surfaces via interactionswith ENaC (20,
21). To test whether CS affected this interaction, we ex-
posed Alexa Fluor 633–labeled rSPLUNC1 to ;13 ciga-
rette puffs of CS or air over 5min.Air-exposed rSPLUNC1
bound to HBEC mucosal surfaces (Fig. 1A, C); however,
CS-exposed rSPLUNC1 failed to bind (Fig 1B, C). To
confirm that CS exposure did not affect fluorescently la-
beled rSPLUNC1, per se, we examined the fluorescence
under cell-free conditions in amultiplate reader.As shown
inFig. 1D,CSdidnot affect the fluorescenceof rSPLUNC1-
Alexa Fluor 633.
CS prevents SPLUNC1 from regulating
ASL height
CSexposure is themain contributor toASLdehydrationas
a result of persistent ENaC activity in the absence of
functional CFTR (16, 17). As SPLUNC1 is an endogenous
negative regulator of ENaC activity, we assessed whether
CS impacted the ability of rSPLUNC1 to regulate ENaC-
led ASL homeostasis. HBECs were loaded with 20 ml
Ringer’s solution that contained rhodamine-dextran with
40 mM rSPLUNC1, CS-exposed rSPLUNC1, or Ringer’s
solution with or without CS as vehicle controls.
Figure 1. CS inhibits rSPLUNC1 
binding to HBEC mucosal sur-
faces. A, B) Typical XZ-confocal 
micrographs of Dylight-labeled 
rSPLUNC1 with or without CS 
(red) binding to the mucosal 
surface of HBECs stained with 
calcein-AM (green). C) Mean  
data showing relative mucosal 
binding of Dylight rSPLUNC1 
with or without CS to HBECs. 
Each symbol represents 1 well on 
the multiwell plate (n = 9 from 3  
donors). D) Control readings for 
Dylight-labeled SPLUNC1 with 
or without CS in Ringer’s solu-
tion in cell-free conditions mea-
sured in a multiplate reader (n = 
9 from 3 donors). ***P , 0.0001 
(Mann-Whitney U test).
CS-Ringer’s had no significant effect on ASL height
compared with naive Ringer’s solution (Fig. 2A, B). Air-
exposed rSPLUNC1 significantly increased ASL height
after 6 h compared with Ringer’s solution with or with-
out CS (Fig. 2A, B). Surprisingly, CS-rSPLUNC1 failed to
elevate ASL height (Fig. 2A, B). To determine whether
these effectswere reversible, CS-rSPLUNC1was dialyzed
overnight in Ringer’s solution. Dialyzed, air-exposed
rSPLUNC1 retained its ability to modulate ASL volume;
however, dialyzed CS-rSPLUNC1 still failed to regulate
ASL volume, which indicates that CS exposure results in
irreversible modifications to SPLUNC1 (Fig. 2C, D).
CS-SPLUNC1 fails to internalize ENaC
CS-rSPLUNC1 failed to regulate ASL volume, which
suggests a failure to regulate ENaC. To test for this, we
transiently expressed different combinations of a-, b-, and
g-ENaC subunits inHEK293T cells, with only one subunit
tagged per transfection with HA andV5 epitopes at the N
and C termini, respectively, as previously described (36).
Surface biotinylation followed by Western blot analysis
was used to determine the amount of plasma mem-
brane and intracellular ENaC after exposure to 40 mM
rSPLUNC1, CS-SPLUNC1, or Ringer’s controls. Similar to
our previous studies, SPLUNC1 significantly reduced
botha-andg-ENaCsubunits at theplasmamembrane and
inwhole-cell lysate (Fig. 3A–C).Consistentwith the lackof
binding and effect on ASL height (Figs. 1 and 2), CS-
rSPLUNC1 failed to internalize a- and g-ENaC subunits,
which indicates that CS blunts the ability of SPLUNC1
to regulate ENaC (Fig. 3A–C). As a result of the ability
of CS to inhibit SPLUNC1-ENaC internalization in
HEK293T cells, we assessed the effect of CS on the
ability of SPLUNC1 to regulate ENaC on HBECs.
CS exposure dimerizes and oxidizes SPLUNC1
As we have shown that the ability of rSPLUNC1 to regu-
late ASL volume and ENaC activity was irreversibly
modified after CS exposure, we next used a proteomic
approach to look for adduct binding to rSPLUNC1. The
Figure 2. CS-exposed rSPLUNC1 cannot regulate ASL height. A) Representative XZ-confocal micrographs of ASL height (red)
6 h after the addition of 20 ml PBS that contained 1 mg/ml of 10-kDa rhodamine-dextran with nondialyzed Ringer’s solution
(vehicle control), CS-exposed Ringer’s solution, or rSPLUNC1 with or without Ringer’s solution. B) Summary of 6 h ASL height
measurements (all: n = 12 from 4 donors). C) Confocal micrographs of ASL heights after the addition of rSPLUNC1 or CS-
exposed rSPLUNC1 that had been dialyzed overnight in Ringer’s solution or vehicle controls. D) Summary of ASL height
measurements of dialyzed samples after 6 h. Each symbol represents 1 transwell [n = 12 (B) and n = 9 (D) from 4 and 3 donors,
respectively]. Scale bars, 5 mm. Statistically significant differences were measured using Kruskal-Wallis test. **P ,0.001.
crystal structure of human rSPLUNC1 revealed a
curved b-sheet flanked by a-helices that together en-
close a hydrophobic core (21) (Fig. 4A). rSPLUNC1 also
contains 2 cysteine residues at C180 and C224 that
may form a disulfide bond (Fig. 4A). Using liquid
chromatography–tandem mass spectrometry analysis,
we detected the majority of SPLUNC1’s sequence after
tryptic and chymotryptic digestion (211/256 aa, 82%
coverage; Fig. 4B), including the peptides that encom-
pass the cysteine residues of SPLUNC1. Proteomic
analysis further revealed both crotonaldehyde and
acrolein modifications to SPLUNC1’s 2 cysteine resi-
dues (positions 180 and 224; Fig. 4C–F). To investigate
whether these cysteine modifications were prevent-
able, we preincubated rSPLUNC1with the antioxidant,
glutathione. This maneuver abolished CS-induced
modifications of rSPLUNC1 (Fig. 4G, H). To determine
whether SPLUNC1’s MW was altered after CS expo-
sure, we performed SDS-PAGE analysis. Under re-
ducing conditions, an additional band, which was
indicative of SPLUNC1 dimerization, was detected af-
ter CS exposure by Western blot analysis (Fig. 4I). Un-
der native/nonreducing conditions, the shift from
monomer to dimer was more pronounced, and the
majority of the protein seemed to be dimerized, which
indicates that CS structurally alters rSPLUNC1 (Fig. 4J).
Figure 3. CS-exposed rSPLUNC1 fails to internalize ENaC. HEK293T cells were transiently transfected with ENaC subunits (i–iii)
as indicated and studied 24 h later. Representative immunoblots and densitometry of membrane and whole-cell protein levels,
respectively: a-ENaC (A), b-ENaC (B), and g-ENaC (C). Whole-cell lysate results are presented as samples normalized to Ringer’s
control. GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was blotted as a loading control for the lysate. Each symbol
represents 1 culture (n = 6 from 6 different experiments). *P , 0.05 (ANOVA).
Figure 4. CS induces adduct binding to rSPLUNC1 cysteine residues. A) Structure of SPLUNC1, which indicates the positions of
cysteine residues C180 (green) and C224 (orange). B) rSPLUNC1 coverage as revealed after chymotryptic digestion. Cleaved N-
terminal signal sequence is highlighted (gray). Cysteines C180 and C224 are highlighted in green and orange, respectively. C, D)
Representative liquid chromatography–tandem mass spectrometry (LC-MS/MS) spectra showing crotonaldehyde adducts
binding to rSPLUNC1’s cysteine residues 180 in peptide IHLVLGDCYHSPHSL (C) and 224 in peptide VLPELVQGNVCPLV-
NEVLR (D). E, F) LC-MS/MS spectra showing acrolein adducts binding to rSPLUNC1’s cysteines residue 180 in
VLGDCTHSPGSL (E) and 224 in peptide VLPELVQGNVCPLVNEVLR (F). G) Modified peptide was not detected in the
presence of 40 mM glutathione. H) Total ion current intensity of crotonaldehyde modified SPLUNC1 fragments. I ) Nonreducing
PAGE stained with gel-code blue showing rSPLUNC1 dimer formation with or without CS exposure. J) Representative Western
blot of rSPLUNC1 with or without CS exposure probed with an anti-SPLUNC1 Ab. Arrows indicate dimers.
SPLUNC1 cysteine residues are critical for ASL
volume regulation
Proteomic analysis indicated crotonaldehyde and acrolein
binding to rSPLUNC1 cysteines. To assess the impact
of these residues on rSPLUNC1 function, we generated
the following SPLUNC1 mutants: rSPLUNC1C180A,
rSPLUNC1C224A, and rSPLUNC1C180/C224A. Both
rSPLUNC1C180A and rSPLUNC1C224A retained the ability
to regulateASLheight (Fig. 5A,B) andwere sensitive toCS
exposure (Fig. 5C–F). In contrast, rSPLUNC1C180A/C224A
failed to regulate ASL height and CS exposure had no
additional effect (Fig. 5G, H), which suggests that at least 1
cysteine was required for SPLUNC1 activity and that CS
binding to both cysteines inhibited function.
Biophysical analysis of the secondary and
tertiary structure of CS-exposed SPLUNC1
Todeterminewhether CS alters the secondary structure of
SPLUNC1, we performed circular dichroism. Despite CS
inducing adduct binding (Fig. 4), therewere no significant
differences in the spectra of air vs.CS-exposed rSPLUNC1
or any of the rSPLUNC1 cysteine mutants (Fig. 6A–D).
Similarly, thesecondarystructureof rSPLUNC1C180A/C224A
was unaffected by CS exposure, despite the mutant
functionally reprising CS rSPLUNC1. These results in-
dicated that CS-induced cysteine adducts do not affect
the secondary structure of SPLUNC1. In contrast to cir-
cular dichroism, dynamic light scattering can accurately
assess protein oligomerization by determining the
hydrodynamic size of each protein. Consistent with
our previous study (21), this technique revealed that
naive/air-exposed rSPLUNC1 was present as a single
peak, which suggests that it predominantly formed
monomers; however, the size distribution graph demon-
strated that CS-SPLUNC1 was visible as additional peaks
between 220 and 400 nm, which indicated aggregation
(Fig. 6E). In contrast to rSPLUNC1, rSPLUNC1C180A and
rSPLUNC1C224Awere detected asmultiple peaks, which
suggests some spontaneous aggregation and, poten-
tially, the formation of intermolecular disulfide bonds,
even without CS exposure (Fig. 6F, G). Of interest, after
CS exposure, these peaks disappeared, which suggests
that CS disrupts any intermolecular disulfide bonds that
may occur in these mutants. Similar to circular dichro-
ism, rSPLUNC1C180A/C224A contained the sameprofile in
the presence or absence of CS, which suggests that it was
incapable of forming ab-unsaturated aldehyde adducts
(Fig. 6H).
SPX-101 structure/function is unhindered by
CS exposure
We have thus far demonstrated that CS exposure altered
the structure and function of rSPLUNC1. Previous reports
have shown that SPX-101 can regulate ENaC-led ASL
absorption in a dose-dependent manner (23). We exposed
SPX-101 to CS and performed proteomic analysis and
functional assays. Proteomic analysis indicated that there
was no adduct formation to SPX-101 after CS exposure
(Fig. 7A). We then treated HBECs with CS-exposed SPX-
101 and found that CS-exposed SPX-101 was still able to
regulate ASL volume (Fig. 7B). Because SPX-101 and CS-
SPX-101 were efficacious at regulating ASL volume in
HBECs,weassessed theabilityof SPX-101andCSSPX-101
to regulate ENaC activity in HBECs by measuring the
amiloride-sensitive transepithelial voltage (VtAMIL). As
amiloride can hyperpolarize the apical membrane and
induce Cl2 secretion, we pretreated all cultures serosally
with bumetanide to inhibit Cl2 uptake. Under baseline
conditions, there was an ;8 mV VtAMIL, which suggests
that ENaC was active (Fig. 7C). SPLUNC1, SPX-101, and
CS SPX-101 caused a significant reduction in VtAMIL,
which is indicative of attenuation of ENaC activity. In
agreement with previous observations, CS-SPLUNC1
failed to attenuate ENaC activity (Fig. 7C).
We have previously demonstrated that SPLUNC1 in-
ternalizes a-ENaC-GFP, which leads to a quenching of
GFP fluorescence in HEK293T cells (37). SPX-101 also in-
duces ENaC internalization (23); therefore, we measured
GFP quenching as a marker for internalization using a
multiplate reader. Accordingly,we transiently transfected
HEK293T cells with a-ENaC-GFP, as well as unlabeled b-
and g-ENaC, and exposed them to SPX-101 with or
without CS for 1 h. Both SPX-101 and CS-SPX-101 de-
creased a-ENaC-GFP fluorescence, which suggests that
SPX-101 could still internalize ENaC (Fig. 7D). In addi-
tion, as a negative control, we expressed GFP-CFTR in
HEK293T cells and observed that fluorescence remained
unchanged after 1 h of incubation with SPX-101 (Fig.
7E). As an additional control, a-ENaC-GFP–transfected
HEK293T cells were exposed to CS, and fluorescence in-
tensity remained unchanged compared with Ringer’s
control (Fig. 7F).
TodeterminewhetherSPX-101 couldhelp increaseASL
hydration in CS-exposed airway epithelia, HBECs were
pretreated with SPX-101 or vehicle and exposed to CS or
air. Consistent with the in vivo phenotype of mucus de-
hydration and our previous in vitro studies (16, 26), ASL
height decreased in CS-exposed HBECs; however, with
SPX-101pretreatment,ASLheightwasmaintained inboth
air- and CS-exposed HBECs compared with vehicle and
CS-exposed controls (Fig. 7G). As prophylactic SPX-101
treatment prevented CS-induced ASL dehydration, we
next assessed whether SPX-101 could also aid in re-
hydration when added to HBECs. For this, we used
HBECs derived from 4 healthy donors and 4 COPD do-
nors. HBECs were exposed to freshly generated CS, and
SPX-101 was added apically 1 h after CS exposure. After
30 min with SPX-101, ASL height of CS-exposed cultures
was significantly increased greater than normal levels,
irrespective of origin, andwasnot significantly different to
ASL height in air-exposed treated SPX-101 cultures (Fig.
7H).
b-ENaC-Tg mice overexpress b-ENaC and develop
obstructive pulmonary disease broadly similar to COPD
(38). SPX-101 has previously been demonstrated to in-
crease the survival ofb-ENaCmicewhenadded soonafter
birth (23). To determine whether CS SPX-101 could have
the same effect, b-ENaC mice were treated with 50 mM
DISCUSSION
We have previously demonstrated that SPLUNC1 cannot
regulate ENaC in acidic cystic fibrosis (CF) ASL (21);
however, the impact of CS exposure on the ability of
SPLUNC1 to function is less clear. Emerging data indicate
Figure 5. SPLUNC1 cysteine
mutants are required for ASL
volume homeostasis. A, B)
HBECs were loaded with 20 ml
Ringer’s solution that con-
tained 1 mg/ml of 10-kDa
rhodamine-dextran and 40 mM
rSPLUNC1, rSPLUNC1C180A,
and rSPLUNC1C224A as indicated
(A), and ASL height was mea-
sured by XZ-confocal microscopy
(B; all: n = 9 from 3 donors).
C–H) rSPLUNC1C180A (C, D),
rSPLUNC1C224A (E, F), and
rSPLUNC1C180/C224A (G, H )
were exposed to CS and cultures
were subsequently loaded with
40 mM of each protein. Repre-
sentative XZ-confocal micro-
graphs of ASL height (red) 6 h
after addition of rSPLUNC1 or
rSPLUNC1 mutants (C, E, G),
and the mean ASL heights are
shown (D, F, H; n = 9 from 3
donors). Scale bars, 5 mm. *P ,
0.01, **P , 0.001 (ANOVA).
SPX-101, 50 mM CS SPX-101, or 50 mM NaCl (control) for 
up to 14 d. SPX-101 significantly increased the survival rate 
to 94% with a once-daily intranasal instillation. Similarly, 
survival with CS-exposed SPX-101 reached 87.5% in mice, 
which further indicates that CS has no effect on SPX-101 
function (Fig. 7I).
that COPD pathogenesis has some similarities with CF.
Beyond the chronic neutrophilia, tobacco exposure chron-
ically inhibits CFTR, likely by internalizing CFTR from
the plasma membrane, which leads to ASL dehydration
(14–16). Whereas CS seems to consistently inhibit CFTR
both in vivo and in vitro, it does not seem to affect ENaC,
which suggests that ENaC inhibition is a potential therapy
to rebalance ion transport in dehydrated COPD airways.
Of importance, ourdatademonstrate that continuedENaC
activity in the absence of CFTR drives this dehydration,
and that pretreatment with an ENaC antagonist pre-
vents CS-induced dehydration (17). SPLUNC1 protein
levels are reduced in bronchoalveolar lavages from ciga-
rette smokers and patients with COPD compared with
Figure 6. CS-induced aggregation of rSPLUNC1. SPLUNC1 and cysteine mutants were exposed to CS. Structure of rSPLUNC1
(A, E), rSPLUNC1C180A (B, F), rSPLUNC1C224A (C, G), and rSPLUNC1C180A/C224A (D, H) was analyzed using circular dichroism
and dynamic light scattering. All data are representative of 3 individual experiments. Black lines, air-exposed rSPLUNC1; red
lines, CS-exposed rSPLUNC1.
Figure 7. SPX-101 does not bind adducts and remains functional after CS exposure. A) Representative liquid chromatography–
tandem mass spectrometry spectrum showing CS-exposed SPX-101 peptide, AALPIPLDQTAA. B) Summary data of ASL height
measurements taken 6 h after mucosal addition of 20 ml Ringer’s solution (control) or SPX-101 in Ringer’s solution with or
without CS exposure (Ringer’s, n = 7; SPX-101 and CS-SPX-101, n = 8). **P, 0.001. C) Amiloride-sensitive Vts (VtAMIL) in HBECs
after 1 h of exposure to SPLUNC1 or SPX-101 as indicated (all: n = 9 from 3 donors). **P, 0.001, ***P, 0.0001 [compared with
Ringer’s control (ANOVA)], #P , 0.01, ##P , 0.001 (compared with CS Ringers), †P , 0.05, ††P , 0.001 (compared with CS
Ringers). D) Change in fluorescence of a-ENaC transiently transfected in HEK293T cells 3 h after incubation with vehicle or
peptide as indicated (all n = 4). **P , 0.001. E) Fluorescence of GFP-CFTR transiently transfected into HEK293T cells after a 3-h
exposure to Ringer’s solution or SPX-101 with or without CS (all: n = 4). F) HEK293T cells transfected with a-ENaC-GFP cells
(continued on next page)
healthy individuals, which has been attributed to neutro-
phil elastase–induced degradation (39). However, the di-
rect effects ofCS on SPLUNC1and its subsequent ability to
regulate ENaC have not yet been investigated.
Our data indicate that fluorescently labeled rSPLUNC1
failed to bind toHBECmucosal surfaces after CS exposure
(Fig. 1). This was not because of CS-induced quenching
of the dye, and rSPLUNC1 remained fluorescent in solu-
tion after CS exposure (Fig. 1D). As expected, this lack
of binding had functional consequences, and after
rSPLUNC1 had been exposed to CS, it also failed to reg-
ulate ASL homeostasis. In contrast, exposing Ringer’s
solution toCS, then adding it to cells did not result inASL
dehydration (Fig. 2A, B), which is consistent with our
previous observation that the components of CS that in-
hibit CFTR are contained in the volatile phase and not in
the water-soluble or tar phases (40). Overnight dialysis in
freshRinger’s solutiondid not reverse these effects,which
suggests that CS irreversibly altered SPLUNC1 and that
this was not a result of potential acidification of Ringer’s
solution by CS exposure (Fig. 2C, D). Although the failure
to absorb excess ASL after the addition of CS-rSPLUNC1
was most likely a result of ENaC dysregulation (20), this
does not prove a direct link between SPLUNC1 and
ENaC. We have recently demonstrated that rSPLUNC1
internalized a- and g-ENaC subunits and targeted them
to the lysosome (37); therefore, we assessed whether CS-
SPLUNC1 could still internalize a- and g-ENaC subunits.
Similar to ASL height assays, the ability of CS-SPLUNC1
to internalize ENaC and reduce ENaC activity were at-
tenuated after CS exposure (Fig. 3A–C), which suggests
that SPLUNC1’s role as an endogenous inhibitor of ENaC
was severely attenuated by CS exposure. HEK293T cells
are an immortalized cell line that has enabled us to in-
vestigate SPLUNC1-ENaC interactions using transfected
wild-type and mutant proteins. For example, we have
previously observed that SPLUNC1-induced a- and
g-ENaC internalization occurs in bothHEK293T cells and
HBECs, which suggests that their use is valid (37). How-
ever, as a caveat, although trafficking may be similar be-
tween the 2 culture systems, the adaptor/chaperone
proteins required may differ.
As the effects of CS were irreversible and resulted in
SPLUNC1 aggregation, we next investigated potential
chemical modifications to rSPLUNC1 using mass spec-
trometry. SPLUNC1 contains 2 cysteine residues—C180
and C224—within its b-sheet region (21), and reducing
SPLUNC1 with DTT abrogated its ability to inhibit
ENaC (19), which suggests that these residues are sensi-
tive to oxidation/reduction. Using an untargeted liq-
uid chromatography–tandemmass spectrometry analysis
approach, we identified that the a,b-unsaturated
aldehydes, crotonaldehyde and acrolein, bind to both of
these residues (Fig. 4C–F). Unsurprisingly, the antioxi-
dant, glutathione, preventedCS-inducedmodifications to
SPLUNC1 cysteines (Fig 4). Crotonaldehyde and acrolein
are present in micromolar concentrations in CS and ex-
hibit strong reactivity toward cysteine residues (41),
which suggests thata,b-unsaturated aldehyde binding to
SPLUNC1may be common in tobacco smokers, and that
disruption of the disulfide bonds causes SPLUNC1 dys-
function. These disulfide bonds have not previously been
directly studied in the context of SPLUNC1; however, CS
exposure to protein-disulfide isomerases results in the
nitrosylation of cysteine modifications, which leads to
alterations in its 3-dimensional structure (42). Similarly,
CS exposure to surfactant protein A also resulted in
modifications to cysteine residues (7). However, whether
these modifications affected the disulfide bond on
surfactant protein A remains to be determined.
As the observed effects of CS on rSPLUNC1 were irre-
versible (Fig. 2), we performed gel electrophoresis to
investigate potential differences in rSPLUNC1’s MW.
We found that CS caused rSPLUNC1 aggregation un-
der nonreducing conditions and that the majority of
SPLUNC1was dimerized (Fig 4J). To investigate whether
cysteines play a role in this dimerization, we analyzed
control and CS rSPLUNC1 by Western blot under re-
ducing conditions. Here, the majority CS-rSPLUNC1 was
present in monomeric form (Fig 4I). The minor amount of
dimerized CS rSPLUNC1 visible under reduced condi-
tions may have been a result of chemical cross-linking by
CS constituents, including acrolein and crotonaldehyde.
Because the majority of CS rSPLUNC1 was not cross-
linked, these data suggest that the loss of function was
related to CS-induced cysteine modifications. We then
used biophysical approaches to confirm these observa-
tions. Consistent with our electrophoresis experi-
ments (Fig. 4), we observed rSPLUNC1 aggregation after
CS exposure by dynamic light scattering for wild-
type SPLUNC1 (Fig. 6E–G). The molecular radius of
rSPLUNC1 was ;6.25 nm; however, after CS exposure,
SPLUNC1’s radius increased to 250–360 nm, indicating
aggregation. On the basis of these data, we propose that
CS-inducedSPLUNC1aggregationdirectly contributes to
its failure to regulate ENaC. Although previous reports
have demonstrated that CS extract significantly increases
ubiquitinated proteins localized in the perinuclear space
inBea2b cells (43), to our knowledge, this is the first report
to demonstrate that CS exposure to secreted airway pro-
teins results in aggregation. On the basis of these data,we
propose that the ability of SPLUNC1 to regulate ASL
volume after CS exposure was a result of SPLUNC1’s al-
tered redox state.
were exposed to CS as a control (all: n = 4. G) HBECs were preloaded with vehicle or peptide, excess ASL was aspirated, cultures
were exposed to CS or air as indicated, and ASL height was measured by XZ-confocal microscopy. N, air; ■, CS cells; ,, SPX-101;
:, CS exposed cells + SPX-101 (all: n = 9). **P , 0.001, ***P , 0.0001 (compared with CS cells). H) Mean ASL height at time
points in HBECs exposed to air or CS followed by SPX-101 where indicated (n = 12 from 4 normal donors and n = 12 from
4 COPD donors). **P , 0.001, ***P , 0.0001 (compared with CS cells), †††P , 0.0001 (compared with air exposed cells, 2-way
ANOVA). I) Kaplan-Meier survival curves for b-ENaC mice treated once daily, starting 2 d after birth, with 50 mM SPX-101 (n =
16), CS-SPX-101 (n = 12), and saline (control, n = 20). Solid black line, SPX-101; hashed line, CS SPX-101 solid gray line, saline.
**P , 0.001 (Wilcoxan match pairs signed rank test, and Kaplan-Meier log-rank analysis).
To better understand the importance of SPLUNC1’s
disulfide bond, we mutated its cysteines to alanines
and used ASL volume homeostasis as a proxy for
ENaC regulation. When either cysteine was mutated—
rSPLUNC1C180A or rSPLUNC1C224A—normal function
and sensitivity toCS exposure remained intact (Fig. 5A–F).
In contrast, the rSPLUNC1C180A, C224A double mutant lost
its ability to regulate ASL volume and was insensitive to
CS exposure (Fig. 5G, H). A schematic summary of the
effect of CS on SPLUNC1 and its cysteine mutants is
summarized Fig. 8. We propose that under normal con-
ditions, the presence of a disulfide bond between residues
C180 and C224 allows rSPLUNC1 to extend its S18 region
and potentially interact with ENaC (Fig. 8Ai). After CS
exposure, crotonaldehyde binds to cysteine residues (Fig.
8Aii), disrupting the disulfide bond to possibly cause a
conformational change in SPLUNC1 that prevents the S18
region from interacting. Of interest, SPLUNC1C180A was
able to retain function (Fig. 5C, D). On the basis of our
data (Fig 6), we hypothesize that the single cysteine mu-
tants form intermolecular disulfide bonds with adjacent
SPLUNC1 molecules to allow the full function of the S18
region (Fig. 8Bi); however, these mutants were still sensi-
tive to CS exposure, which attenuated ASL regulation by
blocking the disulfide bond formation (Fig. 8B). Finally,
the double cysteinemutantwas inactive and insensitive to
CS, which suggests that the missing disulfide bond in-
duces a conformational change that is incompatible with
S18 function (Fig. 8C).
Although previous reports have demonstrated CS can
alter secondary protein structure (42), we found that nei-
ther CS exposure, nor cysteine removal altered the relative
amounts of rSPLUNC1’s a-helix, b-sheet, or disordered
regions (Fig. 6A–C). SPLUNC1 has a hydrophobic core
Figure 8. Summary of CS-induced conforma-
tional changes to SPLUNC1 structure. SPLUNC1
structure was drawn in Pymol (obtained from
Structural Bioinformatics Protein Data Bank,
ID: 4KGH). The S18 region (blue; sequence
GGLPVPLDQTLPLNVNPA) was manually docked
onto residue S43. Cysteines 180 and 224 are
shown in orange and green, respectively. Ai)
Wild-type (WT) SPLUNC1 with the out-
stretched S18 region. Aii) CS-exposed WT
SPLUNC1, with crotonaldehyde binding in-
dicated (arrow), leading to a conformational
change in the S18 region. Bi) SPLUNC1C180A
retains the ability to regulate ENaC by forming
intermolecular disulfide bonds with adjacent
SPLUNC1C180A. Bii) CS-exposed SPLUNC1
C180A
renders function inactive with the separation of
the 2 molecules. Ci) SPLUNC1C180/C224A regu-
latory function is attenuated to conformational
change of structure and the S18 region. Cii) CS
had no additional effect on SPLUNC1C180/C224A
function.
usually shielded by other residues. Indeed, SPLUNC1 has
beendescribed as both a super role protein that canunfold
at the air-liquid interface to reduce surface tension (44) and
as a tubular lipid-binding protein that uses its hydropho-
bic core tobind lipids (45). Thus,we speculate that ablation
of the disulfide bond exposes thehydrophobic core,which
leads to aggregation.Despite the lack of a cysteine residue,
singlemutants could still regulateASL height (Fig. 5), and
we observed spontaneous dimerization, even in the ab-
sence of CS exposure (Fig. 6F, G). These data suggest that,
in the absence of 1 cysteine, SPLUNC1 may form intra-
molecular disulfide bonds that serve to stabilize the mol-
ecule and allow it to perform its normal functions. Of
interest, rSPLUNC1C180A, C224A spontaneously aggregated
and no additional aggregation occurred after CS exposure
(Fig. 6H). On the basis of these data, we propose that CS-
induced SPLUNC1 aggregation after a,b-unsaturated al-
dehydebinding to the 2 cysteines directly contributes to its
failure to regulate ENaC.
Acrolein and crotonaldehyde are major constituents of
CS that are responsible for cysteine adduct binding, the re-
lease of IL-8 in human macrophage cell lines, and the in-
hibition of the production of several proinflammatory
cytokines, including IL-2 and TNF-a (2, 46–48). Glutathione
is an important antioxidant present in the ASL (49), and
a,b-unsaturated aldehyde exposure decreases glutathione
levels, thereby increasing the formation of reactive oxygen
species (3, 50). As the progression of COPD is associated
with increased oxidative stress (51, 52) and reduced anti-
oxidants (50), loss of SPLUNC1 function may be more pro-
nounced as COPD worsens. Detection of adducts on
SPLUNC1andotherproteins in theairwaysof tobaccousers
and patients with COPDmay serve as novel biomarkers of
exposure/harm that can be used to assess the toxicity of
different tobacco products. Indeed, as a biomarker, adduct
formation may have increased sensitivity as it does not re-
quire changes in protein expression to be quantified.
SPX-101 is currently being evaluated as a therapeutic
for the treatment of ASL dehydration/mucus stasis in CF
(23).As SPX-101does not have cysteines, andbecauseCS/
COPD airways are also characterized by ASL/mucus
dehydration (53, 54), we tested the hypothesis that SPX-
101 could treat mucus dehydration in CS-exposed airway
cultures.WhereassomepatientswithCOPDstopsmoking
after diagnosis, many continue, which suggests that air-
inhaled therapy will need to be smoke proof (54). Indeed,
we were unable to detect adduct binding to SPX-101 after
CS exposure, which suggests that it may be useful in this
context (Fig. 7A). Similarly, CS-exposed SPX-101 was still
able to regulate ASL height. As an indicator of ENaC
activity, we measured the amiloride-sensitive voltage
(VtAMIL) across HBECs after mucosal incubation with
SPLUNC1 or SPX-101. As predicted, CS exposure abol-
ished the ability of SPLUNC1 to inhibitVtAMIL. In contrast,
SPX-101 remained CS independent and was able to sig-
nificantly attenuate ENaC activity under these thin film
conditions (Fig. 7). In addition, both SPX-101 and CS SPX-
101were able to internalize a-ENaC, but not CFTR,which
suggests that it is unaffected by CS exposure (Fig. 7).
Furthermore, when added after CS had decreased ASL
volume, SPX-101 was still able to increase ASL hydration
(Fig. 7). Finally, to demonstrate that CS-exposed SPX-101
works in vivo, we used a Tg mouse model in which
b-ENaC was overexpressed, leading to spontaneous CF/
COPD-like lung disease and a 50% mortality rate (24).
Consistent with HBEC experiments, CS-exposed SPX-101
significantly increased b-ENaC mouse survival when
added to lungs via intranasal delivery. Taken together,
these data indicate that SPX-101 may be useful as a treat-
ment for chronic smokers and patients with COPD. An
advantage of using intrinsically disordered peptides, such
as SPX-101, is that they achieve a greater contact area
with their target protein, thus maximizing binding effi-
ciency (56). Furthermore, there is no reason why it cannot
beused in conjunctionwith existingCOPD therapies, such
as bronchodilators, to yield favorable results.
In summary, we have demonstrated by functional
assay and using proteomic approaches that SPLUNC1
structure and function are irreversibly modified by
a,b-unsaturated aldehydespresent inCS. Becausemucus/
ASL dehydration is a component of COPD pathogene-
sis, our results suggest that aldehyde modification of
SPLUNC1 is a key event in the dysregulation of ASL vol-
umehomeostasis. Thepresenceofdysfunctional SPLUNC1
in the COPD lung is overcome by SPX-101, and our results
suggest that SPX-101 could be used as therapy for patients
with COPD who have dehydrated ASL/mucus.
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